Lifecore Biomedical
LFCR
95 hedge funds and large institutions have $285M invested in Lifecore Biomedical in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 13 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 93 → 95 (+2)
4% more capital invested
Capital invested by funds: $275M → $285M (+$10.3M)
2.05% less ownership
Funds ownership: 88.57% → 86.53% (-2%)
11% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 35
95% less call options, than puts
Call options by funds: $13K | Put options by funds: $258K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$6.34M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$3.09M |
| 3 |
WC
Wynnefield Capital
New York
|
+$2.77M |
| 4 |
SCM
SG Capital Management
Chicago,
Illinois
|
+$1.67M |
| 5 |
CSC
Cove Street Capital
El Segundo,
California
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$4.91M |
| 2 |
AC
AltraVue Capital
Bellevue,
Washington
|
-$4.07M |
| 3 |
JGUA
John G. Ullman & Associates
Corning,
New York
|
-$3.89M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.24M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
HSBC Holdings
London,
United Kingdom
| – | -$215K | -20,132 | Closed |
|
|
SFI
102
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$140K | -13,227 | Closed |
|
103
Norges Bank
Oslo,
Norway
| – | -$121K | -11,400 | Closed |
|
|
TI
104
Trexquant Investment
Stamford,
Connecticut
| – | -$119K | -11,239 | Closed |
|
|
SFS
105
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$40K | -3,220 | Closed |
|
106
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$7K | -718 | Closed |
|
|
VCM
107
Versant Capital Management
Phoenix,
Arizona
| – | -$3K | -284 | Closed |
|
LFCR Hedge Fund Activity: Q2 2021 in Review
95 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2021, worth a combined $285M — up 3.7% from $275M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LFCR positions and 13 closed out — a net gain of 2 holders — while 31 added to existing stakes and 35 trimmed.
The largest buyer was 22NW LP, opening a new position worth an estimated $6.34M. The largest seller was Russell Investments Group, cutting an estimated $4.91M.
- 95 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2021, up from 93 in Q1 2021.
- Funds reported $285M of Lifecore Biomedical stock for Q2 2021, up 3.7% quarter-over-quarter.
- 15 funds opened new Lifecore Biomedical positions in Q2 2021 and 13 closed out, a net change of +2 holders.
- The largest Lifecore Biomedical buyer in Q2 2021 was 22NW LP, an estimated $6.34M added.
- The largest Lifecore Biomedical seller in Q2 2021 was Russell Investments Group, an estimated $4.91M sold.
Based on aggregated 13F filings for Q2 2021.